Drugs / LPCN 1154A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06979544 | Jun 2025 → Jan 2026 | postpartum depression | Lipocine Inc. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPCN 1154A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06979544 ↗ |
| Route | Oral | “Oral LPCN 1154A tablets for 48 hours” NCT06979544 ↗ |